Oral fluoroquinolones are widely known to form chelate complexes with metal-containing drugs, resulting in inhibition of their intestinal absorption. However, for intestinal sterilization, the concomitant regimen may be a selective and effective strategy due to decreased absorption of fluoroquinolones result in the retainment of antibiotics at the intestine if the mixture still perpetuated antibacterial activity. Therefore, to clarify whether the mixture of fluoroquinolones and sucralfate affects their antibacterial activity or not, we conducted in vitro study. According from the checkerboard study using a microdilution method with Mueller-Hinton broth, the antibacterial activity of these fluoroquinolones-sucralfate mixtures equaled to the parent fluoroquinolones even in the presence of sucralfate at the molar ratio of 
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INTRODUCTION
Oral fluoroquinolones are commonly administered not only conventional infection diseases caused by microorganisms such as respiratory and urinary tract infections but also prophylaxis use for treatment of endogenous infection in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). [1] [2] [3] [4] Because the endogenous infection induced by Gram-negative bacteria is a clinically significant problem in compromised hosts such as allo-HSCT recipients, 5, 6) and selective intestinal sterilization is a key strategy. 7) Fluoroquinolones generally form stable metal chelate complexes if these were concomitantly administered with drugs containing metal cations such as aluminum or magnesium, which cause inhibition of their intestinal absorption 8) and following suppression of blood fluoroquinolone concentrations. This phenomenon means that high concentration of fluoroquinolone-cation complexes remain in the intestine. Therefore, the concomitant regimen would be a selective and effective strategy for digestive decontamination if antibacterial activity of fluoroquinolones is maintained even in the chelated forms. However, reported antibiotic activity of various fluoroquinolones with metal complexes is controversial. Some described that the reduction of antibacterial activity was observed, [9] [10] [11] and others were not. 12) Therefore, to provide a uniform criterion for commingling usage of fluoroquinolones with sucralfate, we attempted a comparison of antibacterial activity of fluoroquinolones with their sucralfatecomplexes against clinically-isolated bacteria by in vitro study. Here we choose, sucralfate as a metalcontaining drug because it has the most intensive interaction property against fluoroquinolones in comparison with other metal cations. 8, 10, 11) C 2009 The Pharmaceutical Society of Japan Hospital (Kagawa, Japan). Mueller-Hinton broth (MHB), (pH 7.4) which was purchased from Becton, Dickinson & Co., (Franklin Lakes, NJ, U.S.A.) was employed for the determination of the minimal inhibitory concentration (MIC) in serial dilution tests. Antibacterial Activity --An overnight culture of test organism at 35 • C in MHB was diluted with saline to yield an initial inoculum of approximately 10 6 colony forming units (CFU)/ml in each well. The MICs of ten fluoroquinolones against E. coli strain ATCC25922 was defined as the lowest antibiotic concentration inhibiting visible bacterial growth after overnight incubation at 35 • C by turbidity, and each MIC was adopted to the corresponding initial fluoroquinolone concentration for the following experiments. The effect of sucralfate at the concentration range from 0.063 to 4 mg/ml was determined by a two-way full checkerboard design on a 96-well microplate using a two-fold dilution scheme. Antibacterial activity of each sample was defined as the visible bacterial growth after overnight incubation at 35 • C by turbidity. The mixture of sucralfate and each fluoroquinolone was incubated for 1 hr in a shaking incubator at a room temperature before applying to the plate. The incubation period for 1 hr was chosen because Tanaka et al. 13) reported that the chelation of fluoroquinolones with sucralfate was achieved within 1 hr. The supernatant from fluoroquinolone-sucralfate suspension was obtained by centrifugation at 20000 × g for 30 min at room temperature. Statistical Analysis --MICs of fluoroquinolones alone and in combination with sucralfate against clinical isolated strains were compared using Student's t-test and Welch's t-test, as appropriate, respectively. All p-values were two-tailed, and p < 0.05 was considered significant.
MATERIALS AND METHODS

Chemicals
RESULTS AND DISCUSSION
Fluoroquinolones are widely used to treat not only conventional infection diseases but also intestinal sterilization. Meanwhile, fluoroquinolones are prohibited to concomitant administration with drugs that contain aluminum, calcium, or magnesium at the same time as fluoroquinolones due to the dramatic reduction in the oral bioavailability of them by co-administration of metal cations. 8) When viewed from different directions, this phenomenon means that high concentration of fluoroquinolonecation complexes remain in the intestine, and if the complexes could posses their antibacterial activity, the concomitant regimen would be a selective and effective strategy or, at least, unconcerned way for digestive decontamination.
However, there is a little information whether the chelated forms of fluoroquinolones have antibacterial activity or not. Some reports said that the concomitant use of fluoroquinolones and cation-containing drugs caused the reduction of antibacterial activity, [9] [10] [11] and others were not. 12) Therefore, to clarify the degree for the decrease of antibacterial activity of fluoroquinolones by aluminum-containing antacid, we conducted the growth-inhibitory experiments of ten fluoroquinolone against E. coli strain ATCC25922 in MHB in the presence or absence of sucralfate (Table 1) .
Sucralfate was marketed in Japan in 1968 as an antiulcer agent, and that stimulates the defense 16) In this study, the initial concentration of each fluoroquinolone in MHB was determined from the MIC against E. coli strain ATCC25922, and it varied from 0.013 (0.008 µg/ml; TFLX) to 0.197 (0.063 µg/ml; NFLX) µM (Table 1 ). Considering that the free aluminum concentration was expected to 4.83 µM from 0.063 mg/ml sucralfate, all fluoroquinolones studied here could make a complex with dissolved aluminum even at the minimum concentration of sucralfate. It was reported that some fluoroquinolones-aluminum complexes lowered their parent antibacterial activity. 17) However, as shown in Table 1 , inhibitory effect of sucralfate on antibacterial activity of studied ten fluoroquinolones were not observed when sucralfate concentration was 0.063 mg/ml, indicating that the fluoroquinolone-aluminum complex shows antibacterial activity comparable to that of free fluoroquinolones. Interestingly, antibacterial activity was disappeared with the increase of sucralfate (Table 1) . TFLX was less subject to sucralfate (1 mg/ml) followed the rank order CPFX = GFLX > LVFX = NFLX = SPFX > OFLX = PUFX > ENX = LFLX. If fluoroquinolones-aluminum complexes were the critical compounds for antibacterial activity, it would not be affected by sucralfate concentration because sufficient (at least 25 times of aluminum presents in 0.063 mg/ml sucralfate and 0.197 µM NFLX) aluminum was dissolved even at the minimum concentration of sucralfate, and the concentration of fluoroquinolones were constant. According from these results, it was expected that adsorption reaction between fluoroquinolones and sucralfate would exist. In addition, supernatant of each reaction mixture gave no antibacterial activity (Table 1) . Taking into account the results of these experiments, it may be concluded that sucralfate adsorbs not only free fluoroquinolones as described 13) but also fluoroquinolone-aluminum complex under our experimental conditions, and that high concentration of sucralfate (molar ratio of [sucralfate : fluoroquinolone]; 11556 < for CPFX, 166 < for ENX, 6027 < for GFLX, 186 < LFLX, 2773 < for LVFX, 607 < for NFLX, 698 < for OFLX, 3455 < for PUFX, 5877 < for SPFX, and 35616 < for TFLX) inhibits antibacterial activity of parent fluoroquinolones due probably to the increased adsorption. Next, in order to ascertain whether the sucralfate-fluoroquinolone mixture exerts effective antibacterial activity against clinical isolated pathogens or not, we applied two fluoroquinolones (NFLX and CPFX) in combination with or without sucralfate to clinical isolated E. coli and P. aeruginosa strains. In this study, the sucralfate concentration was kept constant (0.063 mg/ml), and the molar ratio of [sucralfate : NFLX] was prepared from 0.02 (512 µg/ml) to 77 (0.125 µg/ml) and [sucralfate : CPFX] was from 0.09 (128 µg/ml) to 728 (0.016 µg/ml) by varying the concentration of these fluoroquinolones. Our preliminary experiments by high-performance liquid chromatography 18) indicate that these fluoroquinolones would be present as the fluoroquinolones-aluminum complexes in the . Taking into account the our results, the combination therapy of sucralfate with, at least, NFLX and CPFX seems to have less affect in the antibacterial activity of these fluoroquinolones under ordinary medical practice except for the absorption processes. 19) It was reported that aluminum hydroxide possessed adsorbent properties for antibiotics including LVFX, OFLX, ENX, and NFLX, 13) which result in the decrease in bioavailability of these drugs. 20) However, there is no information about the antibacterial activity of these adsorbed compounds.
In conclusion, our present data suggests that sucralfate can interact not only by chelate-forming property by dissolved aluminum but also by adsorption reactions, and the chelated forms of each fluoroquinolone retain antibacterial activity even in the presence of the recommended therapeutic doses of sucralfate in clinical practice. At present, some oral aminoglycoside antibiotics are applied for intestinal sterilization such as vancomycin, tobramycin, 21) and neomycin 22) because these drugs are nonabsorbable antibiotics. However, special attention would be paid to issues of ototoxicity, renal insufficiency, and vestibular toxicity in case of large amount of dosage or mucosal lesions are present. In 2007, we had reported the preventive effects of fluoroquinolones such as CPFX or NFLX for endogenous infection in patients receiving various allo-HSCT. 2) Judging from our present result, it seems to be effective strategy to co-administrate fluoroquinolone and sucralfate in order to maintain the fluoroquinolone retention time in the intestine and decrease the absorption into the bloodstream without affect the parent antibiotic activities of fluoroquinolones for intestine sterilization. Further studies are needed to clarify whether this hypothesis is useful or meaningless attempt.
